Host cell genome and episomal DNA (DNA)

The host cell genome and episomal DNA represent the fundamental genetic blueprints within a cell, comprising both the nuclear chromosomal DNA and extrachromosomal elements. The host genome is responsible for storing the hereditary information required for cellular function, growth, and reproduction, while episomal DNA often exists as independent, stable genetic material, frequently associated with persistent viral infections such as Hepatitis B (HBV) or Human Papillomavirus (HPV) [1][2]. In oncology, the genome is a primary target for cytotoxic agents like cisplatin and doxorubicin, which induce DNA damage to trigger apoptosis in rapidly dividing cells [3]. Modern therapeutic interventions have shifted toward precision medicine, utilizing gene editing tools like CRISPR/Cas9 to correct pathogenic mutations directly within the host genome or to target and degrade viral episomes to achieve functional cures for chronic infections [4][5]. Additionally, gene therapies utilize viral vectors to deliver functional genetic material that persists as either integrated genomic DNA or stable episomes to compensate for genetic deficiencies [6]. However, targeting these structures carries significant risks, including off-target genetic modifications and the potential for insertional mutagenesis, which necessitates rigorous safety evaluations in clinical applications [6].

Other names

Genomic DNAChromosomal DNAExtrachromosomal DNAEpisomeCovalently closed circular DNAcccDNANuclear DNA

Drugs targeting the host genome or episomal DNA operate through several distinct mechanisms: chemical modification (alkylation or cross-linking) to inhibit replication, physical intercalation to disrupt transcription, and site-specific enzymatic cleavage (via nucleases like Cas9) to facilitate gene correction or deletion [3][4]. Additionally, gene therapy vectors may integrate new genetic sequences into the host genome or maintain them as stable episomes to restore protein function [5][6].